Atlas.
Sign inStart free trial
TXGNASDAQ · US

10x Genomics, Inc.

Technology · Laboratory Analytical Instruments

TechnologyLaboratory Analytical Instruments
CEO
Serge Saxonov
Founded
—
IPO Date
—
HQ
Pleasanton, CA, United States
Exchange
NASDAQ
Employees
n.a.

Share Price Performance

$39.05 ▲ 135.0%
Last (1 Jul 2026) · $39
Period High · $39.05
Period Low · $0.00
52W: $39.05 – $39.05

Key Metrics

Share Price
$39.05
+1.8% today
Market Cap
$5.0B
P / E
—
EV / Revenue
7.8x
Revenue Growth
+5.3%
year-on-year
Gross Margin
+69.0%
Enterprise Value
$5.0B
52W High
$39.05
52W Low
$0.00
Avg Volume
3.0M
daily

Sources: SEC filings · Market data as of Jul 6, 2026

Shareholders' Structure
12 known institutional holders·$924M total on record·2026-Q1
Fmr LLC
13.9%·$377M
BlackRock, Inc.
7.9%·$214M
Goldman Sachs Group Inc
3.2%·$87M
Geode Capital Management, LLC
2.3%·$62M
State Street Corp
2.0%·$55M
Dimensional Fund Advisors LP
1.6%·$43M
Northern Trust Corp
0.8%·$22M
Renaissance Technologies LLC
0.8%·$21M
Bank Of America Corp
0.8%·$20M
Jpmorgan Chase & Co
0.6%·$16M
Invesco Ltd.
0.2%·$7M
Price T Rowe Associates Inc
0.1%·$3,466
Free Float
65.7%

Sources: SEC filings

Notes: % shown as share of total shares outstanding · Free float = shares outstanding minus all known 13F institutional holdings

What Atlas covers for 10x Genomics, Inc.
Overview10x Genomics, Inc. share price history (10 years), key market statistics, and institutional shareholder structure from SEC 13F-HR filings.Business ModelHow 10x Genomics, Inc. generates revenue — product and service segments, geographic breakdown, key operating metrics, and 10-year business evolution sourced from SEC filings.Financials10x Genomics, Inc.'s complete financial history — 10 years of annual revenue, gross margins, operating income, net income, EPS, and free cash flow from SEC filings, plus 12 quarters of quarterly results.Management Quality10x Genomics, Inc. executive team profiles, insider buying and selling from SEC Form 4, earnings call transcripts, and a track record of guidance delivery vs actual results.Risk Factors10x Genomics, Inc.'s annual risk disclosures from SEC filings — full text, 5-year evolution showing how risks have shifted, and year-on-year delta highlighting new and removed risks.NewsAI-synthesised news digest for 10x Genomics, Inc., updated regularly with key developments, earnings updates, product announcements, and material company events.SentimentInvestor sentiment for 10x Genomics, Inc. aggregated from X.com, Reddit, and Hacker News — discussion themes, Bull and Bear signals, and community analysis.Valuation & Peers10x Genomics, Inc. valuation multiples — P/E, EV/Revenue, EV/EBITDA — compared against a curated set of industry peers using live data from SEC filings. Custom peer selection available.DCF BuilderBuild a discounted cash flow model for 10x Genomics, Inc. with 10 years of pre-filled revenue, margins, and cash flow data from SEC filings. Adjust growth rates, WACC, and terminal assumptions.Atlas AnalysisAtlas AI research synthesis for 10x Genomics, Inc. — business model, financial health, management quality, risk profile, and institutional ownership, grounded exclusively in SEC filings.

Unlock the full analysis

9-tab institutional research sourced directly from SEC filings. No tips, no scores — the same process professional investors use.

7-day free trial · Plus & Pro · No charge during trial